FP158
3499N
Dr.Sanjana Vinod
| Membership No | Author Name | Mobile | |
|---|---|---|---|
| 3499N | Dr.Sanjana Vinod | sanjanachoondal@gmail.com | 9915507520 |
Uvea
Real-World Experience with JAK Inhibitors Across the Spectrum of Non-infectious Ocular Inflammation
Purpose:To evaluate the efficacy,steroid-sparing effect,multimodal imaging outcomes,tear cytokine profile& safety of JAKinhibitors in refractory noninfectious ocular inflammatory diseases Methods:Retrospective observational study of 75 patients treated with tofacitinib, baricitinib or upadacitinib.Clinical features, imaging, treatment response, steroid use, safety and tear cytokines were analysed Results:Mean age-40.2±18.6yrs; panuveitis was most common-41.3%. Tofacitinib was used in 92%, with patients receiving a median of 2 prior DMARDs. Overall response was 89.3%.OCT&FFA confirmed reduced inflammatory activity with significant steroid sparing.Tear IL-17A & MMP-9 were elevated in active and clinically quiet fellow eyes, suggesting subclinical bilateral inflammation Conclusion: JAKi are effective steroid-sparing agents for refractory ocular inflammation. Imaging confirmed sustained disease control, while tear IL-17A and MMP-9 may serve as non-invasive biomarkers of subclinical disease
| Membership No | Author Name | Mobile | |
|---|---|---|---|
| 717 | Dr.Padmamalini Mahendradas | m.padmamalini@gmail.com | 9845551862 |
| 1662N | Dr.Ankush Ashok Kawali | akawali332@gmail.com | 9632368641 |
| 2965 | Dr.Sai Bhakti Mishra | drsaibhakti@gmail.com | 8105490765 |